Not Yet Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT06860789
AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AK135 for the Treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients With Malignant Tumors
Sponsor: Akeso
Interventions
AK135
Updated 1 time since 2025 Last updated: Feb 28, 2025 Started: Feb 28, 2025 Primary completion: Mar 31, 2026 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06860789, this PHASE1 trial focuses on Chemotherapy-induced Peripheral Neuropathy (CIPN) and remains actively recruiting participants. Sponsored by Akeso, it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Akeso
Data source: Akeso
For direct contact, visit the study record on ClinicalTrials.gov .